Loading
Radiation Therapy and Dosimetry / Nanoplatforms for Cancer Theranostics · Journal article
Nano Today · August 13, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical proof-of-concept study demonstrating that BSA-modified PdPt nanosheets reduce tumor hypoxia and enhance radiotherapy efficacy in vivo through catalytic oxygen generation, ROS amplification, and photothermal effects. The work is mechanistic and exploratory, suitable for hypothesis generation but insufficient to guide clinical translation without further validation and controlled comparative studies.
Preclinical in vivo study. Tumor-bearing animal models (species, strain, and eligibility criteria not specified).. Intervention: PdPt nanosheets modified with bovine serum albumin (PdPt@BSA) administered as monotherapy and in combination with radiotherapy and near-infrared irradiation..
PdPt@BSA amplified X-ray-induced cellular damage evidenced by increased ROS generation and enhanced DNA double-strand breaks PdPt@BSA alleviated tumor hypoxia through catalytic oxygen generation with downregulation of HIF-1α In vivo PdPt@BSA-based combination therapy markedly suppressed tumor growth with minimal systemic toxicity
In vivo PdPt@BSA-based combination therapy markedly suppressed tumor growth with minimal systemic toxicity
This nanoparticle platform represents an early-stage candidate for hypoxia-modulated radiotherapy. Clinicians and translational researchers should view this as concept validation requiring rigorous comparative efficacy studies, toxicology profiling, and mechanistic validation before clinical development is warranted.
Preclinical in vivo study of a novel nanoparticle platform demonstrating mechanistic effects on tumor hypoxia and radiosensitivity in animal models, without clinical trial data or direct comparison to standard therapy.
As stated by the source record.
This nanoparticle platform represents an early-stage candidate for hypoxia-modulated radiotherapy. Clinicians and translational researchers should view this as concept validation requiring rigorous comparative efficacy studies, toxicology profiling, and mechanistic validation before clinical development is warranted.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
With the global rise in cancer incidence, the development of effective and safe therapeutic strategies remains an urgent priority. Although radiotherapy (RT) is widely used in clinical oncology, its therapeutic efficacy is often compromised by the hypoxic tumor microenvironment, which induces radioresistance. Therefore, alleviating tumor hypoxia to enhance radiosensitivity has emerged as a promising strategy for improving radiotherapeutic outcomes. Herein, we developed bovine serum albumin (BSA)-modified PdPt nanosheets (PdPt@BSA) with intrinsic catalytic activity, radiosensitizing capability, and photothermal properties for enhanced cancer therapy. PdPt@BSA effectively amplified X-ray-induced cellular damage, as evidenced by increased reactive oxygen species (ROS) generation, aggravated mitochondrial dysfunction, and enhanced DNA double-strand breaks. Notably, PdPt@BSA alleviated tumor hypoxia through catalytic oxygen generation, accompanied by the downregulation of hypoxia-inducible factor-1α (HIF-1α), thereby overcoming hypoxia-induced radioresistance and significantly enhancing the therapeutic efficacy of radiotherapy. In addition, PdPt@BSA exhibited strong near-infrared absorption and outstanding photothermal conversion efficiency, which further potentiated tumor radiosensitization under near-infrared irradiation. In vivo studies demonstrated that PdPt@BSA-based combination therapy markedly suppressed tumor growth with minimal systemic toxicity. Moreover, PdPt@BSA partially induced immunogenic cell death, suggesting their potential to activate antitumor immune responses. Overall, this work presents a PdPt nanosheet-based nanoplatform that integrates catalytic hypoxia modulation, radiosensitization, and photothermal enhancement, providing a promising strategy for improving cancer radiotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.